Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Validating Immunohistochemistry Assays for Novel Biomarkers in Preclinical Oncology Studies Across Europe

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Validating Immunohistochemistry Assays for Novel Biomarkers in Preclinical Oncology Studies Across Europe

Validating Immunohistochemistry Assays for Novel Oncology Biomarkers

CELL & GENE | RNA | BIOLOGICS

    What are the primary challenges in validating an IHC assay for a novel, uncharacterized biomarker?

    The principal difficulties involve confirming antibody specificity and managing potential tissue cross-reactivity without an established positive control. Establishing a dynamic range for quantification is also complex when a gold-standard reference material does not exist. The process requires a multi-faceted approach using engineered cell lines or tissues with known target expression to build a foundation of evidence for the antibody’s performance.

    How do you establish assay sensitivity and specificity for a target with no commercially available reference materials?

    We establish performance by correlating IHC results with data from orthogonal methods. For example, we compare staining intensity in tissue samples with corresponding mRNA expression levels from RNAseq or protein abundance from mass spectrometry. We also utilize cell lines engineered to overexpress or knock out the target protein, creating definitive positive and negative controls to confirm the antibody binds only to the intended target.

    What GxP considerations apply to IHC assay validation for preclinical toxicology studies in Europe?

    For studies supporting regulatory submissions in the EMEA region, validation must align with EMA expectations. This includes comprehensive documentation of antibody specificity, a standardized and validated staining protocol, and objective, pre-defined scoring criteria. All procedures, from reagent qualification to pathologist training, must be documented within a GxP framework to ensure data integrity and reproducibility for IND-enabling safety assessments.

The validation of immunohistochemistry (IHC) assays for novel oncology biomarkers demands a systematic approach that moves beyond simple antibody screening. A robust validation package integrates orthogonal data correlation, an understanding of species-specific expression patterns, and rigorous GxP documentation. This ensures the delivery of reliable, interpretable data from nonclinical studies to support confident decision-making for clinical development programs.

The Challenge of Novel Biomarker Expression in Oncology

Developing a therapeutic against a novel target introduces a significant challenge: the absence of validated reagents to measure its expression and distribution. A reproducible IHC assay is fundamental for confirming target engagement, evaluating pharmacodynamic effects, and assessing safety in non-target tissues. Without a properly validated assay, study data can be misleading, jeopardizing program timelines and investment.

A successful validation framework is built on several pillars:

  • Antibody Specificity: Screening multiple antibody clones against engineered cell lines or tissues to identify the most specific and sensitive reagent.

  • Orthogonal Method Correlation: Comparing IHC staining patterns with molecular data (e.g., RNAseq) to confirm that the antibody accurately reflects target expression.

  • Cross-Species Evaluation: Assessing antibody performance in relevant nonclinical species and understanding potential differences in target presentation.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Translating Preclinical Insights Across Species

Understanding how a biomarker is expressed across different tissues and species is a key component of a successful translational strategy. Research into reporter gene expression has shown that even well-characterized systems can exhibit unexpected tissue-specific profiles, which underscores the need to validate an assay in the specific biological context of the study (PMID: 17510373). An antibody that performs well in one tissue may not be suitable in another due to differences in protein conformation or the presence of cross-reactive epitopes.

Subtle biological differences between species can have a significant impact. For example, work engineering AAV vectors has revealed that species-specific variations in cell surface glycans can alter vector biodistribution and target engagement (PMID: 39001819). This principle extends to IHC: the presentation of a biomarker on a cell surface can differ between a preclinical model and human tissue. Acknowledging and investigating these potential differences during assay validation is a requirement for generating translatable data that supports confident program decisions.

Animal Welfare and GxP Compliance

Our programs are fully accredited by AAALAC and operate in compliance with USDA regulations.

Our >100,000 sq ft facility operates under a unified GxP quality system, ensuring that all pathology data is generated to the highest standards for regulatory submission. This rigorous approach has supported an 18-24 month average IND timeline for our partners and a 100% IND success rate since 2019. Franklin Biolabs as a brand was launched in 2024, building upon this established operational history.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

Comparative Methodologies for IHC Validation

Selecting the right tools to validate an IHC assay is dependent on the specific target and available resources. A multi-pronged approach provides the strongest evidence package for an antibody’s performance.

Method Application Strengths Limitations
Western Blot Confirms antibody binding to a protein of the correct molecular weight. Simple, direct assessment of specificity. Denaturing conditions may not reflect protein conformation in tissue.
Engineered Cell Lines Creates definitive positive and negative controls (knockout/overexpression). Unambiguous confirmation of target specificity. Does not replicate complex tissue architecture or matrix effects.
Orthogonal Platforms Correlates IHC staining with RNAseq or proteomics data from the same samples. Provides quantitative, independent confirmation of expression patterns. Requires access to multi-omic datasets and bioinformatics support.
Tissue Microarrays Screens antibody performance across a wide range of normal and diseased tissues. High-throughput assessment of specificity and cross-reactivity. Small core size may not be representative of heterogeneous tissues.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities